

Trying 01082...Open

PLEASE ENTER HOST PORT ID:

PLEASE ENTER HOST PORT ID:x

LOGINID:d186tmc

PASSWORD:

* * * * * RECONNECTED TO U.S. Patent & Trademark Office * * * * *

SESSION RESUMED IN FILE 'USPAT' AT 11:26:52 ON 27 APR 1998

FILE 'USPAT' ENTERED AT 11:26:52 ON 27 APR 1998

= e Guo, Yajun/in

E#	FILE	FREQUENCY	TERM
--	---	-----	----
E1	USPAT	4	GUO, XIN S/IN
E2	USPAT	1	GUO, XIN SHENG/IN
E3	USPAT	0 -->	GUO, YAJUN/IN
E4	USPAT	1	GUO, YANPING/IN
E5	USPAT	1	GUO, YIH DER/IN
E6	USPAT	2	GUO, YIHONG/IN
E7	USPAT	3	GUO, YILI/IN
E8	USPAT	3	GUO, YIMIN/IN
E9	USPAT	2	GUO, YUCHUAN/IN
E10	USPAT	1	GUO, YUH KUEN/IN
E11	USPAT	1	GUO, ZHANGENG/IN
E12	USPAT	1	GUO, ZHICHAO/IN

= s bispecific antibod?/clm

26 BISPECIFIC/CLM
7686 ANTIBOD?/CLM
L4 17 BISPECIFIC ANTIBOD?/CLM
((BISPECIFIC(W)ANTIBOD?) /CLM)

= t 14 1-17

1. 5,736,342, Apr. 7, 1998, Biosensor for detecting the presence of chosen analytes; Bernard J. Van Wie, et al., 435/7.2, 7.8, 819 [IMAGE AVAILABLE]

2. 5,731,168, Mar. 24, 1998, Method for making heteromultimeric polypeptides; Paul J. Carter, et al., 435/69.1, 69.7, 70.1, 71.1, 172.1, 172.3; 530/300, 350, 387.1, 387.3; 536/33.1, 23.4, 23.5, 23.53 [IMAGE AVAILABLE]

3. 5,723,585, Mar. 3, 1998, Method of purifying cardiac hypertrophy factor; Joffre Baker, et al., 530/413, 350, 380; 930/140 [IMAGE AVAILABLE]

4. 5,712,136, Jan. 27, 1998, Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein; Thomas J. Wickham, et al., 435/172.3, 235.1, 320.1; 530/350 [IMAGE AVAILABLE]

5. 5,693,764, Dec. 2, 1997, Nucleotide or nucleoside photoaffinity compound modified antibodies, methods for their manufacture and use thereof as diagnostics and therapeutics; Boyd E. Haley, et al., 530/391.1; 436/547; 530/391.3, 391.5, 391.7, 391.9 [IMAGE AVAILABLE]

6. 5,658,568, Aug. 19, 1997, Cytotoxic drug therapy; Kenneth Dawson Bagshawe, 424/134.1, 131, 136.1, 155.1, 183.1, 809; 436/319; 514/2; 530/350, 387.3, 387.7, 389.7, 391.7 [IMAGE AVAILABLE]

7. 5,624,806, Apr. 29, 1997, Antibodies to cardiac hypertrophy factor and uses thereof; Joffre Baker, et al., 435/7.1, 331, 344.1; 530/387.3, 387.9, 388.85, 391.3 [IMAGE AVAILABLE]

8. 5,601,819, Feb. 11, 1997, Bispecific antibodies for selective immune regulation and for selective immune cell binding; Johnson T. Wong, et al., 424/136.1; 435/5, 7.2, 7.24; 530/387.3, 388.1, 388.2, 388.22 [IMAGE AVAILABLE]

9. 5,596,081, Jan. 21, 1997, Nucleotide or nucleoside photoaffinity compound modified antibodies, methods for their manufacture and use thereof as diagnostics and therapeutics; Boyd E. Haley, et al., 530/391.1; 436/547; 530/391.3, 391.5, 391.7, 391.9 [IMAGE AVAILABLE]

10. 5,582,996, Dec. 10, 1996, Bifunctional antibodies and method of preparing same; Peter J. Curtis, 435/7.1, 7.9, 69.6, 69.7; 436/542; 530/387.3, 391.3 [IMAGE AVAILABLE]

11. 5,573,920, Nov. 12, 1996, Antibodies, and methods for their use; Beverley J. Randle, 435/7.9, 7.91, 7.92, 172.2, 326, 972, 975; 436/518, 548, 819; 530/387.3, 391.1 [IMAGE AVAILABLE]

12. 5,545,405, Aug. 13, 1996, Method for treating a mammal suffering from cancer with a cho-glycosylated antibody; Martin J. Page, 424/133.1, 130.1, 143.1, 172.1, 174.1; 435/70.3, 71.1, 320.1; 530/387.1, 388.1, 388.22, 388.73, 388.75, 389.1, 389.6, 389.7 [IMAGE AVAILABLE]

13. 5,545,404, Aug. 13, 1996, Method for treating a mammal suffering from a T-cell mediated disorder with a CHO-Glycosylated antibody; Martin J. Page, 424/133.1, 130.1, 143.1, 173.1, 174.1; 435/70.3, 71.1, 320.1; 530/387.1, 388.22, 388.73, 388.75, 388.8, 389.1, 389.6, 389.7 [IMAGE AVAILABLE]

14. 5,545,403, Aug. 13, 1996, Method for treating a mammal by administering a CHO-glycosylated antibody; Martin J. Page, 424/133.1, 130.1, 135.1, 136.1, 138.1, 143.1, 147.1, 150.1, 159.1, 172.1, 174.1; 435/70.3, 71.1, 320.1; 530/387.1, 388.1, 388.22, 388.73, 388.75, 389.1, 389.6, 389.7 [IMAGE AVAILABLE]

15. 5,523,210, Jun. 4, 1996, Bispecific antibody determinants; Henry P. Paulus, 435/7.91; 436/537, 546, 548, 819; 530/387.3 [IMAGE AVAILABLE]

16. 5,496,549, Mar. 5, 1996, Bispecific monoclonal antibodies, thrombolytic agent and method of cell lysis; Hiroh Yamazaki, et al., 424/158.1, 94.63, 134.1, 136.1, 145.1, 182.1; 530/387.3, 388.1, 388.25, 391.7 [IMAGE AVAILABLE]

17. 4,444,878, Apr. 24, 1984, Bispecific antibody determinants; Henry P. Paulus, 435/7.1; 204/403; 422/55; 435/7.5, 7.91, 18, 25, 28, 175, 177, 179, 188, 287.2, 287.9, 805, 810, 817, 962, 964, 966, 969; 436/512, 518, 528, 530, 548, 808 [IMAGE AVAILABLE]

= s CD28 or CD-28

122 CD28
42034 CD
1152641 28
32 CD-28
(CD(W)28)

L5 147 CD28 OR CD-28

= s 15 and (CD28/clm OR CD-28/clm)

14 CD28/CLM
3407 CD/CLM
120347 28/CLM
0 CD-28/CLM
((CD(W)28) /CLM)
L5 14 L5 AND (CD28/CLM OR CD-28/CLM)

= t 16 1-14

1. 5,712,149, Jan. 27, 1998, Chimeric receptor molecules for delivery of co-stimulatory signals; Margo P. Roberts, 435/252.3, 69.7, 320.1; 530/350; 536/23.4 [IMAGE AVAILABLE]

2. 5,693,760, Dec. 2, 1997, Recombinant antibodies for human therapy; Roland A. Newman, et al., 536/23.53; 435/252.3, 320.1 [IMAGE AVAILABLE]

3. 5,686,281, Nov. 11, 1997, Chimeric receptor molecules for delivery of co-stimulatory signals; Margo P. Roberts, 435/172.3, 7.1, 7.2, 69.7; 536/23.4 [IMAGE AVAILABLE]

4. 5,681,722, Oct. 28, 1997, Recombinant antibodies for human therapy; Roland A. Newman, et al., 435/69.7, 6, 91.2; 530/387.3; 536/23.53, 24.33 [IMAGE AVAILABLE]

5. 5,658,570, Aug. 19, 1997, Recombinant antibodies for human therapy; Roland A. Newman, et al., 424/184.1; 435/69.6, 70.21, 172.2, 172.3; 530/388.22; 935/96 [IMAGE AVAILABLE]

6. 5,637,481, Jun. 10, 1997, Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell; Jeffrey A. Ledbetter, et al., 435/69.6, 69.1, 69.7, 172.1, 320.1, 326, 328, 332 [IMAGE AVAILABLE]

7. 5,616,491, Apr. 1, 1997, Knockout mice; Tak W. Mak, et al., 435/354, 172.3, 320.1, 355; 536/23.1; 800/2, DIG.1; 935/22, 70 [IMAGE AVAILABLE]

8. 5,601,819, Feb. 11, 1997, Bispecific antibodies for selective immune regulation and for selective immune cell binding; Johnson T. Wong, et al., 424/136.1; 435/5, 7.2, 7.24; 530/387.3, 388.1, 388.2, 388.22 [IMAGE AVAILABLE]

9. 5,580,756, Dec. 3, 1996, B7IG fusion protein; Peter S. Linsley, et al., 435/69.7, 91.1; 530/350, 387.1, 387.3, 395; 536/23.4 [IMAGE AVAILABLE]

10. 5,557,032, Sep. 17, 1996, Knockout mice; Tak W. Mak, 800/2; 424/9.2; 435/172.3, 320.1; 800/DIG.1, DIG.4; 935/11, 70 [IMAGE AVAILABLE]

11. 5,525,503, Jun. 11, 1996, Signal transduction via **CD28**; Christopher E. Fudd, et al., 435/375; 530/330 [IMAGE AVAILABLE]

12. 5,521,288, May 28, 1996, CD28IG fusion protein; Peter S. Linsley, et al., 530/387.3; 435/7.2, 7.92, 69.1, 69.7, 91.1, 252.3, 252.33, 320.1; 530/300, 350, 387.1, 395, 409, 866, 867, 868; 536/23.1, 23.4, 23.53 [IMAGE AVAILABLE]

13. 5,474,897, Dec. 12, 1995, Screening assay for the identification of novel immunosuppressives using cultured T cells; Arthur Weiss, et al., 435/6, 69.1, 70.4 [IMAGE AVAILABLE]

14. 5,434,131, Jul. 18, 1995, Chimeric CTLA4 receptor and methods for its use; Peter S. Linsley, et al., 514/2; 424/133.1; 514/12; 530/350,

= s gp55

L7 33 GP55

= s gp55/clm

L8 2 GP55/CLM

= t 1+

1. 5,547,834, Aug. 20, 1996, Recombinant CMV neutralizing proteins; Richard F. Spaete, et al., 435/5; 424/186.1, 230.1; 435/69.3, 172.1; 530/350; 935/65 [IMAGE AVAILABLE]

= t 2

2. 5,169,753, Dec. 8, 1992, Method and kit for detecting human retrovirus; Valerie L. Ng, et al., 435/5, 7.1, 235.1, 239, 810, 948, 975 [IMAGE AVAILABLE]

= s (gp55 or gp-55) and tumor?

33 GP55

4212 GP

443490 55

8 GP-55

(GP(W) 55)

31573 TUMOR?

L8 11 (GP55 OR GP-55) AND TUMOR?

= t 19 1-11

1. 5,728,520, Mar. 17, 1998, Immunoreactive polypeptide compositions; Amy J. Weiner, et al., 435/5; 530/350 [IMAGE AVAILABLE]

2. 5,677,274, Oct. 14, 1997, Anthrax toxin fusion proteins and related methods; Stephen H. Leppla, et al., 514/2 [IMAGE AVAILABLE]

3. 5,670,153, Sep. 23, 1997, Immunoreactive polypeptide compositions; Amy J. Weiner, et al., 424/189.1, 228.1; 435/5; 530/350 [IMAGE AVAILABLE]

4. 5,670,152, Sep. 23, 1997, Immunoreactive polypeptide compositions; Amy J. Weiner, et al., 424/189.1, 228.1; 435/5; 530/350 [IMAGE AVAILABLE]

5. 5,651,933, Jul. 29, 1997, Specific immune system modulation; Richard L. Edelson, et al., 424/534, 85.7; 514/825, 866 [IMAGE AVAILABLE]

6. 5,554,505, Sep. 10, 1996, Method and apparatus for optically screening microscopic cells; Constance M. Hajek, et al., 435/7.21, 7.2, 7.23, 7.24 [IMAGE AVAILABLE]

7. 5,462,733, Oct. 31, 1995, Immune system modulation using psoralens activated with visible light; Richard L. Edelson, et al., 424/93.71, 534, 577; 435/2; 604/4 [IMAGE AVAILABLE]

8. 5,348,859, Sep. 20, 1994, Method and apparatus for obtaining an absolute white blood cell subset count and white blood cell multipart differential; Robert F. Brunhouse, et al., 435/7.24, 7.2, 7.21, 7.23 [IMAGE AVAILABLE]

9. 5,292,654, Mar. 8 1994, Mutant EPO receptor and uses therefor;
Akihiko Yoshimura, et al., 435/355, 6, 69.4, 69.5, 69.6, 530/350, 351;
536/23.5; 935/10, 11, 66, 70, 72 [IMAGE AVAILABLE]

10. 5,169,753, Dec. 8, 1992, Method and kit for detecting human
retrovirus; Valerie L. Ng, et al., 435/5, 7.1, 235.1, 239, 810, 948, 975
[IMAGE AVAILABLE]

11. 5,108,920, Apr. 28, 1992, Retrovirus isolated from human lymphoma
cell lines; Valerie L. Ng, et al., 435/239, 235.1, 372 [IMAGE AVAILABLE]

=> logoff hold

SESSION WILL BE HELD FOR 30 MINUTES
U.S. Patent & Trademark Office SESSION SUSPENDED AT 11:32:12 ON 27 APR 199
8
Connection closed by remote host